ArticleGastroenterology and hepatology from bed to bench2024
To vaccinate or not: hepatitis a seroprevalence in institutionalized patients with intellectual disability.
Article in Gastroenterology and hepatology from bed to bench, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Our goal was to assess the need for vaccination and preventive measures in this vulnerable population. Background: HAV is the most common form of acute viral hepatitis, transmitted primarily via fecal-oral route. Therefore, poor hygiene and close contact among institutionalized people are associated with higher HAV infection prevalence. We sought to determine the seroprevalence of anti-HAV antibodies among institutionalized individuals with intellectual impairments in light of Iran's falling trend in HAV antibody prevalence. Methods: In this cross-sectional study, we evaluated the seroprevalence of total and IgM anti-HAV antibodies of 254 institutionalized people with intellectual disabilities. Total and IgM anti-HAV antibodies of the blood samples of these people were determined by ELISA method. Results: The seroprevalence of total and IgM anti-HAV antibodies among institutionalized people with intellectual disability were 15.4% and 0.4% respectively. In comparison to other institutionalized patients, individuals who were elderly and had spent more time in the institutions exhibited a higher prevalence of anti-HAV antibodies (p-values= 0.011 and <0.001, for example). Conclusion: Based on our study, intellectually disabled people have a low prevalence of anti-HAV antibodies, which increases with age and the duration of institutionalization. Therefore, vaccination is necessary to prevent serious infection in these people.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.